Insider Buying: BeyondAirInc . (NASDAQ:XAIR) CEO Acquires $49,080.00 in Stock

BeyondAirInc . (NASDAQ:XAIR) CEO Steven A. Lisi purchased 12,000 shares of BeyondAirInc . stock in a transaction that occurred on Wednesday, November 13th. The shares were bought at an average price of $4.09 per share, with a total value of $49,080.00. Following the transaction, the chief executive officer now owns 581,318 shares of the company’s stock, valued at approximately $2,377,590.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

XAIR opened at $4.03 on Friday. The firm’s 50-day moving average is $4.42. The company has a market capitalization of $42.99 million, a price-to-earnings ratio of -4.80 and a beta of -0.29. BeyondAirInc . has a fifty-two week low of $3.11 and a fifty-two week high of $6.25.

BeyondAirInc . (NASDAQ:XAIR) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.63 million. On average, analysts anticipate that BeyondAirInc . will post -1.28 EPS for the current fiscal year.

XAIR has been the subject of several research reports. Oppenheimer initiated coverage on shares of BeyondAirInc . in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $9.00 price target for the company. ValuEngine lowered shares of BeyondAirInc . from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Zacks Investment Research lowered shares of BeyondAirInc . from a “hold” rating to a “sell” rating in a research report on Saturday, October 19th.

About BeyondAirInc .

Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Recommended Story: What is the QQQ ETF?

Insider Buying and Selling by Quarter for BeyondAirInc   . (NASDAQ:XAIR)

Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.